现代放化疗时代每日分割胸部放疗早期介入对局限期小细胞肺癌患者无生存获益:一项系统综述与Meta分析
该系统综述与Meta分析检索2000年1月至2022年11月数据库,纳入10项研究共10164例可分析患者,比较每日分割胸部放疗早期与晚期介入的疗效。晚期胸部放疗较早期未显著增加死亡风险(HR 1.01,95%CI 0.84-1.20,p=0.94),未显著增加进展风险(HR 0.94,95%CI 0.80-1.11,p=0.48),并有利于减轻3级及以上食管炎(OR 0.42,p=0.01)。作者认为这是首个支持在现代每日分割同步放化疗中晚期介入胸部放疗的Meta分析,并提出需进一步开展前瞻性研究。
要点
- 晚期较早期胸部放疗未显著增加死亡风险(HR 1.01,95%CI 0.84-1.20,p=0.94)
- 晚期较早期胸部放疗未显著增加进展风险(HR 0.94,95%CI 0.80-1.11,p=0.48)
- 晚期胸部放疗有利于减轻3级及以上食管炎(OR 0.42,p=0.01)
核心结论
- 在现代每日分割同步放化疗的局限期小细胞肺癌患者中,晚期介入胸部放疗较早期介入未显著增加死亡风险(HR 1.01,95%CI 0.84-1.20,p=0.94),且可能不损害生存并减少严重急性毒性。
- 作者认为这是首个支持在现代每日分割同步放化疗中晚期介入胸部放疗的Meta分析,并提出需进一步开展每日分割胸部放疗时机的前瞻性研究。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA指南检索2000年1月至2022年11月多个数据库,排除以每日两次胸部放疗为基础的研究。
- 共纳入10项研究、10164例可分析患者,以晚期胸部放疗的生存风险比(HR)为主要效应量,从各研究内部按每日分割胸部放疗时机(早期 vs 晚期)的比较中合并。
- 「早期」通常指同步化疗1-2周期内开始胸部放疗。
主要发现
- 晚期胸部放疗较早期未显著增加死亡风险(HR 1.01,95%CI 0.84-1.20,p=0.94),所有敏感性分析和预设亚组分析结果相似。
- 晚期胸部放疗较早期未显著增加进展风险(HR 0.94,95%CI 0.80-1.11,p=0.48)。
- 晚期胸部放疗有利于减轻3级及以上食管炎(OR 0.42,p=0.01),肺炎(OR 0.62,p=0.38)和中性粒细胞减少(OR 0.57,p=0.11)无显著差异。
- 未发现发表偏倚证据。
关键数值与推荐
- 晚期较早期胸部放疗的死亡风险:HR 1.01,95%CI 0.84-1.20,p=0.94。
- 晚期较早期胸部放疗的进展风险:HR 0.94,95%CI 0.80-1.11,p=0.48。
- 晚期较早期胸部放疗的3级及以上食管炎:OR 0.42,p=0.01。
- 晚期较早期胸部放疗的肺炎:OR 0.62,p=0.38;中性粒细胞减少:OR 0.57,p=0.11。
临床怎么用
- 原文结论认为,在现代每日分割同步放化疗的局限期小细胞肺癌患者中,晚期介入胸部放疗可能不损害生存并可预防严重急性毒性。
- 作者提出需进一步开展每日分割胸部放疗时机的前瞻性研究。
局限性
- 原文结论提出需进一步开展每日分割胸部放疗时机的前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: When concurrent chemoradiotherapy (CCRT) is administered for limited-stage small cell lung cancer (LS-SCLC), the early incorporation of thoracic radiotherapy (TRT) is generally recommended. However, it is controversial if this approach is really beneficial with most commonly used daily fractionated TRT in the modern era. METHODS: A systematic literature search was performed using several databases following the PRISMA guidelines from Jan 2000 to Nov 2022. We excluded twice-daily TRT-based studies. The hazard ratio (HR) for survival following late TRT as a primary effect size was pooled from comparisons within individual studies according to the timing of daily fractionated TRT (early vs. late). RESULTS: A total of 10 studies including 10,164 analyzable patients met all inclusion criteria. 'Early' timing usually referred to TRT within 1-2 cycles of concurrent chemotherapy. The pooled results demonstrated that the risk of death was not significantly increased following late TRT compared with early TRT (HR 1.01, 95% CI 0.84-1.20, p = 0.94). All sensitivity analysis and planned subgroup analyses showed similar results. In comparison with early TRT, late TRT did not significantly increase the risk of progression (HR 0.94, 95% CI 0.80-1.11, p = 0.48). Furthermore, late TRT was beneficial in alleviating grade 3 or higher esophagitis (OR 0.42, p = 0.01), but no significant differences was found in pneumonitis (OR 0.62, p = 0.38), and neutropenia (OR 0.57, p = 0.11). No evidence of publication bias was found. CONCLUSIONS: This is the first meta-analysis to support the late incorporation of TRT in managing patients with LS-SCLC undergoing daily fractionated CCRT in the modern era. This approach may not compromise survival and can prevent severe acute toxicities. Further prospective studies of the daily fractionated TRT timing are warranted.
引用
- Kim BH, Song C, Kim HJ, et al. No survival benefit with early incorporation of thoracic radiotherapy using daily fractionation in patients with limited-stage small cell lung cancer undergoing chemoradiotherapy in the modern era: A systematic review and meta-analysis. Radiother Oncol. 2023. PMID: 37150449. doi:10.1016/j.radonc.2023.109696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。